Technical Analysis for ALLO - Allogene Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 2.14 | 4.15% | 0.09 |
ALLO closed down 3.3 percent on Wednesday, November 20, 2024, on 1.11 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 4.15% | |
| Stochastic Buy Signal | Bullish | 4.15% | |
| Lower Bollinger Band Walk | Weakness | 4.15% | |
| New 52 Week Low | Weakness | 4.15% | |
| Wide Bands | Range Expansion | 4.15% | |
| Down 3 Days in a Row | Weakness | 4.15% | |
| Down 4 Days in a Row | Weakness | 4.15% | |
| Down 5 Days in a Row | Weakness | 4.15% | |
| Oversold Stochastic | Weakness | 4.15% | |
| Hammer Candlestick | Bullish | 0.71% |
| Alert | Time |
|---|---|
| Up 3% | about 1 hour ago |
| 60 Minute Opening Range Breakout | about 1 hour ago |
| Down 2 % | about 3 hours ago |
| Down 1% | about 3 hours ago |
| Up 2% | about 3 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 10/31/2024
Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Stem Cell Cell Therapy Cell Biology Therapies For Cancer Adoptive Cell Transfer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Stem Cell Cell Therapy Cell Biology Therapies For Cancer Adoptive Cell Transfer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.775 |
| 52 Week Low | 1.99 |
| Average Volume | 2,202,140 |
| 200-Day Moving Average | 3.13 |
| 50-Day Moving Average | 2.71 |
| 20-Day Moving Average | 2.68 |
| 10-Day Moving Average | 2.60 |
| Average True Range | 0.22 |
| RSI (14) | 31.97 |
| ADX | 20.51 |
| +DI | 16.99 |
| -DI | 36.04 |
| Chandelier Exit (Long, 3 ATRs) | 2.71 |
| Chandelier Exit (Short, 3 ATRs) | 2.64 |
| Upper Bollinger Bands | 3.37 |
| Lower Bollinger Band | 1.98 |
| Percent B (%b) | 0.05 |
| BandWidth | 52.00 |
| MACD Line | -0.14 |
| MACD Signal Line | -0.03 |
| MACD Histogram | -0.1065 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.28 | ||||
| Resistance 3 (R3) | 2.28 | 2.21 | 2.24 | ||
| Resistance 2 (R2) | 2.21 | 2.15 | 2.21 | 2.22 | |
| Resistance 1 (R1) | 2.13 | 2.12 | 2.10 | 2.13 | 2.21 |
| Pivot Point | 2.06 | 2.06 | 2.04 | 2.06 | 2.06 |
| Support 1 (S1) | 1.98 | 2.00 | 1.95 | 1.98 | 1.89 |
| Support 2 (S2) | 1.91 | 1.97 | 1.91 | 1.88 | |
| Support 3 (S3) | 1.83 | 1.91 | 1.86 | ||
| Support 4 (S4) | 1.83 |
